Evidence map›Paper›PMID 41094592›Full record

ArticleCell communication and signaling : CCS2025

Molecular cargo of small EVs from NSCLC patient BALF and plasma: unveiling their role in airway inflammation and immune regulation in a novel human 3D bronchial model.

Magdalena Dlugolecka, Jacek Szymanski, Lukasz Zareba, Karolina Soroczynska, Zuzanna Homoncik, Malgorzata Polubiec-Kownacka, Ewa Frankiewicz, Diana Wierzbicka, Kannathasan Thetchinamoorthy, Joanna Domagala-Kulawik and 1 more

Abstract read
In one paragraph

Article in Cell communication and signaling : CCS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Magdalena DlugoleckaDepartment of Biochemistry, Medical University of Warsaw, Warsaw, Poland.
Jacek SzymanskiInternational Institute of Molecular and Cell Biology in Warsaw, Warsaw, Poland.
Lukasz ZarebaDepartment of Biochemistry, Medical University of Warsaw, Warsaw, Poland.
Karolina SoroczynskaDepartment of Biochemistry, Medical University of Warsaw, Warsaw, Poland.
Zuzanna HomoncikDepartment of Biochemistry, Medical University of Warsaw, Warsaw, Poland.
Malgorzata Polubiec-KownackaDepartment of Surgery, Institute of Tuberculosis and Lung Diseases, Warsaw, Poland.
Ewa FrankiewiczDepartment of Medical Informatics and Telemedicine, Medical University of Warsaw, Warsaw, Poland.
Diana WierzbickaLaboratory of Regenerative Medicine, Medical University of Warsaw, Warsaw, Poland.
Kannathasan ThetchinamoorthyLaboratory of Regenerative Medicine, Medical University of Warsaw, Warsaw, Poland.
Joanna Domagala-KulawikDepartment of Internal Medicine, Pulmonary Diseases and Allergy, Medical University of Warsaw, Warsaw, Poland.
Malgorzata Czystowska-KuzmiczDepartment of Biochemistry, Medical University of Warsaw, Warsaw, Poland. mczystowska@wum.edu.pl.ORCID http://orcid.org/0000-0001-9169-6194

Funding

Medical University of Warsaw Young Investigator Grant 1WK/2/M/MB/N/22/23National Science Centre OPUS 14 2017/27/B/NZ6/01990NAWA BPI/PST/2021/1/00071/U/00001
6 · The paper itself

Abstract

backgroundTumor-derived small extracellular vesicles (EVs) play a crucial role in modulating immune responses and shaping the tumor microenvironment; however, their functional impact on airway immunity in NSCLC remains largely unexplored. This study represents the first attempt to investigate the immunomodulatory and tumor-promoting effects of NSCLC-derived EVs in a human 3D bronchial airway model, which closely mimics the human lung microenvironment.

methodsEVs were isolated from the plasma and bronchoalveolar lavage fluid (BALF) of NSCLC patients and analyzed via nanoparticle tracking analysis (NTA) and high-resolution imaging flow cytometry. The lymphocyte compositions of the matched blood and BALF samples were profiled. To assess the functional effects of EVs, we employed a pioneering in vitro 3D airway coculture model that combines primary human airway epithelial cells and alveolar macrophages at the air‒liquid interface. Proteomic analysis of EV-treated cells and their secretome was performed to identify key molecular pathways underlying EV-driven immunomodulation.

resultsSurprisingly, no significant molecular differences were detected between EVs from cancerous (cBALF) and opposite (oBALF) lung compartments, despite a localized increase in regulatory T cells (Tregs) in the cBALF, suggesting regional immunosuppression. Plasma-derived EVs exhibited highly diverse, patient-specific molecular signatures but were not directly correlated with clinical or immune parameters. Functional studies of EVs with high and low surface molecular cargo in a 3D airway model revealed that both EV subgroups promoted monocyte/macrophage recruitment, angiogenesis, and epithelial-to-mesenchymal transition (EMT) via MCP-1 secretion and induced an immunosuppressive airway microenvironment, enhancing IL-10 production and shifting macrophages toward a tumor-promoting M2 phenotype. Proteomic analysis revealed distinct differentially expressed protein (DEP) profiles across epithelial and macrophage populations, ultimately resulting in protumorigenic and immunosuppressive outcomes. Notably, functional enrichment analysis of macrophages revealed that EV-driven M2 polarization occurred through the suppression of EGFR activity, a previously underrecognized mechanism that links EV-mediated immune suppression to lung cancer progression.

conclusionsThis study provides the first functional evidence that NSCLC-derived EVs drive immune suppression and tumor-supportive changes in a human 3D airway model, closely mimicking in vivo lung conditions. The identification of EGFR suppression as a driver of macrophage polarization underscores the need to consider macrophage-specific EGFR regulation in anti-EGFR therapies to prevent unintended protumorigenic effects. These findings pave the way for future studies exploring EV cargo, such as miRNAs, as potential therapeutic targets in NSCLC.

Indexed as

BronchiBronchoalveolar Lavage FluidCarcinoma, Non-Small-Cell LungExtracellular VesiclesInflammationLung NeoplasmsModels, BiologicalHumansTumor MicroenvironmentBALFEGFRExtracellular vesiclesImmunoregulationIn vitro 3D human airway modelMacrophage polarizationNSCLCProteomic profilingTumor immune evasion

Identifiers

PMID41094592
PMCPMC12522870

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.